Last reviewed · How we verify

Akorn, Inc. — Portfolio Competitive Intelligence Brief

Akorn, Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
AKF-1 AKF-1 phase 3 Small molecule Unknown Unknown
Benzyl Alcohol Lotion 5% Benzyl Alcohol Lotion 5% phase 3 Pediculicide Dermatology / Parasitic Infection

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abivax S.A. · 1 shared drug class
  2. Altman Biomedical Consulting Pty. Ltd. · 1 shared drug class
  3. Guangdong Hengrui Pharmaceutical Co., Ltd · 1 shared drug class
  4. Health Research, Inc. · 1 shared drug class
  5. Imperial College London · 1 shared drug class
  6. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  7. Nanjing Sanhome Pharmaceutical, Co., Ltd. · 1 shared drug class
  8. Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Akorn, Inc.:

Cite this brief

Drug Landscape (2026). Akorn, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/akorn-inc. Accessed 2026-05-17.

Related